Members of the Copenhagen Study Group for Liver Diseases are: J. T. Balsløv; M. Bjørneboe; P. Christoffersen; K. Eghøje; V. Faber; S. Gjørup; B. Harvald; K. Iversen; O. Jessen; E. Juhl; H. E. Jørgensen; A. R. Krogsgaard; S. A. Nørregaard; T. Steen Olsen; H. Poulsen; F. Quaade; L. Ranek; F. Raaschou; Å. C. Thomsen; N. Tygstrup, and P. Winkel.
Changes of laboratory variables with time in cirrhosis: Prognostic and therapeutic significance
Article first published online: 6 DEC 2005
Copyright © 1985 American Association for the Study of Liver Diseases
Volume 5, Issue 5, pages 843–853, September/October 1985
How to Cite
Christensen, E., Schlichting, P., Fauerholdt, L., Juhl, E., Poulsen, H. and Tygstrup, N. (1985), Changes of laboratory variables with time in cirrhosis: Prognostic and therapeutic significance. Hepatology, 5: 843–853. doi: 10.1002/hep.1840050523
- Issue published online: 6 DEC 2005
- Article first published online: 6 DEC 2005
- Manuscript Accepted: 22 MAY 1985
- Manuscript Received: 24 JUL 1984
The time change of laboratory variables in cirrhosis was studied by analysis of data from 488 patients with cirrhosis included in a controlled clinical trial of long-term prednisone vs. placebo.
In the placebo group, a marked regression towards normal was seen within 3 months of entry into the trial (increase in serum albumin, acetylcholinesterase, cholesterol, hemoglobin and decrease in erythrocyte sedimentation rate). The subsequent course did not show a clear pattern, except for a slight increase in serum bilirubin and decrease in albumin. When studied in relation to the time of death in patients dying from a “hepatic” cause, marked increase in bilirubin and decrease in prothrombin index, albumin and cholesterol were seen in the year prior to death with little change before that time.
In the prednisone group, a more marked decrease in bilirubin, SGOT, alkaline phosphatase, γ-globulin, sulfobromophthalein retention, erythrocyte sedimentation rate and increase in leukocytes, prothrombin index and cholesterol were seen during the first 3 months. In relation to time of death from a “hepatic” cause, similar changes were seen as in the placebo group except that alkaline phosphatase increased and cholesterol did not decrease.
A beneficial effect of prednisone on survival, as expressed by a previously developed therapeutic index, was associated with decrease in SGOT, alkaline phosphatase and γ-globulin within the first 3 months. An increase in SGOT during prednisone seemed to be associated with harmful effects of therapy.